Introduction
T2D, diabetes mellitus, puerariae, rhizoma atractylodis lanceae, hypoglycemic, Diabetes, TCM, diabetes
DIABETES MELLITUS, SECONDARY, DIABETES, TYPE 2 DIABETES, CORTEX, DIABETES
Diabetes is becoming an increasingly serious global public health issue. The International Diabetes Federation (IDF) shows that patients with diabetes mellitus are on the rapid rise worldwide, and the number of patients with diabetes worldwide is expected to reach 783 million by 2045 (Therefore, there is an urgent need for new drugs that are effective with minimal side effects and favorable hypoglycemic effects, as well as relieving clinical symptoms. Traditional Chinese medicine (TCM) has been applied in the treatment of diabetes for thousands of years. In recent years, TCM has made significant progress in modernization and globalization. Jinlida granule is a Chinese patent medicine composed of 17 Chinese herbs (Ginseng, rhizoma polygonati, rhizoma atractylodis lanceae, sophorae flavescentis, ophiopogon japonicus, rehmanniae, polygoni multiflori, dogwood, poria perrin, eupatorium, coptis chinensis, anemarrhena, epimedium, salvia, puerariae, semen litchi, and cortex lycii radices). It was approved by the China Food and Drug Administration (CFDA) as a treatment drug for type 2 diabetes (T2D) in 2005 (National Drug Approval No. Z20050845) and has been widely used in clinical practice (Though the efficacy and safety of Jinlida, as well as its potential action mechanisms, were elucidated, the role of improving clinical symptoms in Jinlida has yet to be studied. Hence, in this work, we conducted a secondary analysis based on the previous randomized controlled trial (